Somewhere in Australia right now, a clinic has an Instagram post about Ozempic. It mentions weight loss. It tags a happy patient. It has been up for six months.
That post is illegal.
Not "grey area" illegal. Not "technically non-compliant." Illegal under the Therapeutic Goods Act 1989. The kind of illegal that comes with fines up to $1.65 million for individuals.
In 2024-2025, the TGA removed over 3,000 online advertisements for weight-loss therapeutic goods. They issued more than $1 million in fines across 19 entities. And they have made it very clear — weight loss advertising is a priority enforcement area for 2026-2027.
If you run a clinic that offers weight-loss services, this is not background noise. This is a direct warning.
What the TGA Actually Did
The numbers tell the story.
The TGA's advertising compliance team conducted a comprehensive sweep. Over 3,000 online ads pulled. Nineteen entities hit with infringement notices totalling more than $1 million. Several cases escalated to court-enforceable undertakings.
The biggest targets were telehealth companies. Midnight Health received $198,000 across 10 infringement notices for advertising prescription weight-loss medicines directly to consumers. Collectively, telehealth businesses were fined over $300,000. Your Solution Compounding Pharmacy received a court-enforceable undertaking for semaglutide advertising.
It was not just the large operators. Myers Pharmacy was fined $18,780 for a single Ozempic ad.
One ad. Nearly $19,000.
Meanwhile, more than 50 practitioners are under AHPRA investigation for inappropriate prescribing linked to advertising claims. The TGA and AHPRA are working together on this. If your advertising draws TGA attention, AHPRA may not be far behind.
The 7 Violations That Got Those Ads Pulled
The TGA's Therapeutic Goods Advertising Code identifies seven common violations behind the enforcement action:
1. Advertising prescription-only medicines to the public.
This is the primary violation. Ozempic, semaglutide, tirzepatide — these are Schedule 4 medicines. You cannot advertise them to the public. Not on your website. Not on social media. Not in your clinic brochure. If a consumer can see it, it is a breach.
2. Naming a prescription medicine in any public-facing content.
Even saying "We prescribe Ozempic" on your website constitutes advertising under the Act. Mentioning a prescription medicine by brand or generic name in any public-facing material counts. Your AHPRA advertising obligations sit on top of this — not instead of it.
3. Using before-and-after photos for weight loss.
Before-and-after images that suggest specific weight-loss outcomes breach the Code. They imply guaranteed results and the TGA considers them misleading. If you are using them on social media, they need to come down. This aligns with AHPRA's cosmetic advertising restrictions.
4. Testimonials implying specific outcomes.
"I lost 15kg in three months!" — paid or unpaid, this kind of testimonial breaches the Code. Patient stories that imply a specific weight-loss result are treated as misleading advertising. Even reposting a patient's own social media post counts.
5. Failing to include required disclaimers.
Weight-management advertising must prominently state the need for a healthy diet and exercise. Not buried in fine print. Not in a hashtag. Prominently displayed. Most of the pulled ads omitted this entirely.
6. Products not listed on the ARTG.
If you are advertising a therapeutic good for weight loss, it must be on the Australian Register of Therapeutic Goods. Compounding pharmacies promoting custom semaglutide formulations were caught here. If it is not on the ARTG, you cannot advertise it.
7. Influencer promotion treated as personal opinion.
Under the Act, social media promotion by influencers is advertising. Paying an influencer — or even gifting product — to promote a weight-loss therapeutic good is unlawful advertising. Your clinic is liable. Not just the influencer.
The "Disease Awareness" Grey Area
Novo Nordisk and Eli Lilly have been accused of running "disease awareness" campaigns that function as de facto advertising for their weight-loss drugs. These campaigns do not name specific products. Instead, they promote "obesity as a disease" messaging, direct consumers to "talk to your doctor," and fund patient advocacy groups.
It is technically legal. Barely.
When multinational pharmaceutical companies run disease-awareness campaigns, they have legal teams reviewing every word. They know exactly where the line is. They have the resources to defend themselves.
Your clinic does not.
If you are copying the "disease awareness" approach — talking about obesity management, metabolic health, GLP-1 receptor agonists without naming brands — you are walking a tightrope without a net. The TGA has the discretion to determine whether your content is advertising based on its overall impression. Not just its literal words.
A small clinic posting "Ask us about medical weight management" with a stock photo of a slim person? The TGA can — and does — treat that as implied prescription medicine advertising.
The law looks at substance over form. What matters is the overall impression on a reasonable consumer. Not your intent.
2026-2027: The Enforcement Escalation
The TGA has published its compliance priorities for 2026-2027. Weight loss is explicitly listed as one of 12 key focus areas. The five priority pillars indicate where enforcement is heading:
- Safeguarding therapeutic goods — protecting supply chain integrity
- Educate to empower — helping consumers identify dodgy claims
- Protect those most at risk — vulnerable populations targeted by weight-loss ads
- Leverage digital capability — targeting AI-generated misinformation and misleading endorsements
- Strengthen enforcement — larger fines, faster action
"Digital capability" means they are improving their ability to find your social media posts. "Strengthen enforcement" means bigger penalties and fewer warning letters.
The maximum penalty for corporations is now $16.5 million per breach. For individuals, $1.65 million. The TGA is increasingly using civil penalty provisions rather than warning letters.
The era of receiving a polite letter first is ending.
Your Clinic's 5-Minute Advertising Audit
Open your clinic's website and social media in another tab. Run through this checklist.
Your website:
- Does any page mention Ozempic, Wegovy, Mounjaro, semaglutide, or tirzepatide by name?
- Do you have before-and-after weight-loss photos?
- Does any page say "we prescribe" or "we offer" a specific prescription medicine?
- Do weight-loss service pages include the diet-and-exercise disclaimer?
- Are all advertised products listed on the ARTG?
Your social media:
- Have you posted about specific weight-loss medicines in the last 12 months?
- Have you reposted patient testimonials mentioning specific outcomes?
- Have you paid or gifted anyone to promote your weight-loss services?
- Do your weight-loss posts include required health disclaimers?
Your Google presence:
- Does your Google Business Profile mention prescription weight-loss medicines?
- Do any Google Ads reference specific prescription products?
If you ticked even one box, you have a compliance exposure. If you ticked three or more, you are in the same category as the clinics that were fined.
What to Do If You Are Non-Compliant
Do not panic. But act fast.
Step 1: Remove obvious breaches today. Take down any content naming prescription weight-loss medicines. Delete before-and-after weight-loss photos. Remove patient testimonials referencing specific outcomes. Today. Not next week.
Step 2: Audit everything else this week. Go through every page of your website, every social media post from the last two years, every Google Ad, every patient-facing document.
Step 3: Rewrite your weight-loss service pages. You can still promote weight-loss services. You cannot name prescription medicines or imply specific outcomes. Focus on your clinical approach, qualifications, and consultation process.
Step 4: Train your team. Everyone who posts on behalf of your clinic needs to understand these rules. One uninformed post from a well-meaning team member can cost $18,780.
Step 5: Set up ongoing review. The rules change. New medicines get scheduled. TGA guidance evolves. Quarterly review of all patient-facing content is the minimum standard.
Stop Guessing. Start Knowing.
Most clinics that were fined did not think they were doing anything wrong. They thought mentioning Ozempic was being transparent. They thought patient testimonials were authentic marketing. They thought "disease awareness" content was safe.
They were wrong. And it cost them.
The difference between a clinic that gets fined and one that does not is not luck. It is knowledge — knowing what the Advertising Code actually says, where the lines are, and what changed last quarter.
AHCRA's AI-powered website compliance audit runs 51 checks across your website and patient-facing materials, covering TGA, AHPRA, ACCC, and Privacy Act requirements simultaneously. It identifies specific violations — including the weight-loss advertising issues the TGA is actively enforcing — and provides actionable remediation guidance. For clinics that want to know exactly where they stand before the TGA finds them, the audit replaces guesswork with certainty.
Because the TGA is not sending warning letters anymore. They are sending invoices.